Michael J. Fitzpatrick
52 IP cases indexed. Covers patent matters.
Cases Presided Over
52 cases indexed | Page 1 of 2
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR against the ’013 single‑cell sequencing patent resulted in the Board finding all 28 claims unpatentable as obvious over prior publications by Linnarsson and McCloskey. The petition’s obviousness arguments were accepted and the patent owner’s defenses were rejected.
Guardant Health, Inc. v.Cold Spring Harbor Laboratory
Guardant Health’s IPR resulted in all 28 claims of the 10,697,013 B1 patent being held unpatentable for obviousness over prior‑art tagging methods. The Board affirmed the petitioner’s combination of Linnarsson and McCloskey references.
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA, LLC successfully petitioned against Smart Denture Conversions, LLC's patent, leading to institution of IPR proceedings. The Board found a reasonable likelihood that claims are unpatentable under both anticipation (102) and obviousness (103).
Straumann USA, LLC et al. v.Smart Denture Conversions, LLC.
Straumann USA successfully petitioned for institution in a Post-Grant Review challenging Smart Denture Conversions' dental implant patent (12156781). The Board found likelihood of unpatentability based on indefiniteness and lack of written description/enablement. This sets a precedent regarding the sufficiency of disclosure in complex medical device claims.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their dispute over U.S. Patent 11,070,530, leading to a joint motion that terminated the IPR proceeding before it was instituted.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, resulting in a Board‑ordered termination of IPR2025-00752 covering patent 10,044,689.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial. The Board terminated the proceeding on the parties' joint motion.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, resulting in the Board terminating the proceedings. The joint motion and stipulation with prejudice ended the challenge to patent 10,171,433.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their patent dispute, leading to the termination of three IPRs before any trial was instituted.
USAA Federal Savings Bank v.PACid Technologies, LLC
USAA Federal Savings Bank and PACid Technologies settled their IPR dispute before trial, leading the PTAB to terminate IPR2025-00697 and related proceedings. The settlement was documented via a Joint Stipulation for Dismissal with Prejudice filed in federal court.
ZEPP HEALTH CORPORATION v.Worcester Polytechnic Institute
Zepp Health filed an IPR against Worcester Polytechnic Institute’s patent 10,653,362. The parties settled the dispute before a trial, and the Board terminated the proceeding, keeping the settlement confidential.
Zepp Health Corporation v.University of Connecticut
Zepp Health and the University of Connecticut settled their IPR dispute over Patent 10,278,647 B2. The Board granted a joint motion to terminate, ending the proceeding before trial.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to institute IPR against Seikagaku Corporation's patent (11236318) based on grounds of lack of written description and obviousness. The Board found sufficient evidence at this preliminary stage, allowing the challenge to proceed into full litigation.
Charles River Laboratories, Inc. v.Seikagaku Corporation
Charles River Laboratories successfully petitioned to invalidate Seikagaku Corporation's patent claims related to endotoxin detection. The Board found grounds for invalidity under 35 U.S.C. § 102 and § 112, specifically citing anticipation by a prior publication.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB that multiple claims of Helsinn Healthcare's anti-emetic patent were unpatentable. The Board granted institution based on obviousness (103) over several prior art references, paving the way for a full trial.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR against Helsinn Healthcare's '515 patent covering anti-emetic agents. The Board found a reasonable likelihood of prevailing based on obviousness (103) and prior art, allowing the challenge to proceed.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully convinced the PTAB to institute IPR proceedings against Helsinn Healthcare S.A.'s patent covering anti-emetic agents for oncology treatment. The Board found a reasonable likelihood that numerous claims would be unpatentable under 35 U.S.C. § 103 based on prior art references.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS successfully petitioned to institute IPR proceedings against Helsinn Healthcare S.A.'s anti-emetic patent (8623826). The Board found a reasonable likelihood of prevailing on independent claim 19, allowing the challenge based on obviousness over prior art like MASCC and Hoffmann.
AZURITY PHARMACEUTICALS, INC. v.Helsinn Healthcare S.A.
AZURITY PHARMACEUTICALS, INC. successfully secured institution of its IPR against Helsinn Healthcare S.A.'s patent (9186357) for anti-emetic agents. The Board found a reasonable likelihood that several claims would be unpatentable over prior art, specifically regarding the combination of triple-drug CINV treatment and superior NK antagonists.
lululemon usa inc. et al. v.Nike, Inc.
The PTAB issued a Final Written Decision finding all 21 challenged claims unpatentable. The Board determined that the prior art (Nishida and Zuckerman) anticipated or rendered obvious the claimed textile manufacturing methods, specifically regarding simultaneous knitting and planar configuration.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
Curio Bioscience, Inc.'s IPR challenge against Prognosys and 10X Genomics was denied by the PTAB. The Board found that Petitioner failed to demonstrate a reasonable likelihood of prevailing on grounds of obviousness (over Cantor/Armani) and anticipation (by Frisen).
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding that the asserted claims were not obvious or anticipated by the prior art. The Board specifically rejected arguments linking Cantor to spatial analysis in tissue sections.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR against Prognosys/10X Genomics, finding no grounds for invalidity based on obviousness (Cantor/Armani) or anticipation (Frisen). The Board concluded that the prior art did not teach the necessary combination elements of spatially encoded biological assays.
Curio Bioscience, Inc. v.Prognosys Biosciences Inc. et al.
The PTAB denied Curio Bioscience's IPR challenge against Prognosys and 10X Genomics, finding no reasonable likelihood of prevailing on grounds of anticipation (102), obviousness (103), or written description (112). The Board upheld the validity of the challenged claims in spatial omics/assay systems technology.
Curio Bioscience et al. v.Prognosys Biosciences Inc. et al.
The PTAB denied the IPR petition brought by Curio Bioscience against Prognosys and 10X Genomics, finding that the challenged claims were not obvious over Cantor or anticipated by Frisen. The Board upheld the Patent Owner's position regarding spatial analysis in tissue samples.
Garmin International, Inc. et al. v.Saris Equipment, LLC
Garmin and Saris Equipment jointly moved to end the IPR over patent 10,434,394 after reaching a settlement. The Board granted the motion, terminating the proceeding and sealing the settlement agreement.
Garmin International, Inc. et al. v.Saris Equipment, LLC
The PTAB granted institution for an IPR challenging Garmin's patent, finding a reasonable likelihood of unpatentability based on prior art anticipation and obviousness arguments against the '394 patent.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully petitioned to institute an IPR against Stratus Medical regarding a neurotomy system patent (10925664). The Board found reasonable likelihood of success on the obviousness grounds, targeting claims 1-29.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical successfully navigated the institution phase of an IPR against Stratus Medical's RF neurotomy patent (10736688). The Board found a reasonable likelihood of success on multiple grounds, allowing the case to proceed to trial.
Avanos Medical, Inc. v.Stratus Medical, LLC
Avanos Medical, Inc. successfully convinced the PTAB to institute an IPR against Stratus Medical, LLC's '688 patent. The Board found a reasonable likelihood of success based on obviousness grounds (35 U.S.C. § 103) using prior art combinations like Racz and Lee.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.